Reports Q4 revenue $14.029M, consensus $14.62M. "We have begun to see positive results from the growth initiatives we commenced over a year ago, with 22% global end user demand growth year over year in ILUVIEN sales driven by our U.S. segment growth of 23% followed by our international segment growth of 21%," said Rick Eiswirth, Alimera’s President and Chief Executive Officer. "Building on the improved foundation of our strengthened capital structure and balance sheet, we are looking forward to continued growth in 2023."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALIM:
- Alimera Sciences Announces 2022 Financial Results and Business Update
- Alimera Sciences (ALIM) Q4 Earnings Cheat Sheet
- Alimera Sciences announces transactions to bolster balance sheet
- Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update
- Alimera Sciences appoints Roger Sawhney to board of directors
